# SNF Platform Study of HR+/ HER2-advanced Breast Cancer

> **NCT05594095** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 620 (estimated)

## Conditions studied

- Breast Neoplasm
- Breast Cancer
- Hormone Receptor Positive Tumor
- HER2-negative Breast Cancer
- Advanced Breast Cancer

## Interventions

- **DRUG:** PIK3CA inhibitor
- **DRUG:** AKT inhibitor
- **DRUG:** Carrelizumab
- **DRUG:** Famitinib
- **DRUG:** Fluzoparib
- **DRUG:** Dalpiciclib
- **DRUG:** SHR-A1811
- **DRUG:** Everolimus
- **DRUG:** Aromatase Inhibitors or Fulvestrant
- **DRUG:** Goserelin
- **DRUG:** TPC
- **DRUG:** Sorafenib
- **DRUG:** Apatinib
- **DRUG:** SHR-A1921
- **DRUG:** SHR-A2102
- **DRUG:** SHR-A2009
- **DRUG:** SHR-1167
- **DRUG:** SHR-6209
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT05594095
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-30
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 620 (ESTIMATED)
- **Last updated:** 2024-10-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05594095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05594095, "SNF Platform Study of HR+/ HER2-advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05594095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*